News | Published:

Controversial egg-producing stem cells promise better IVF

Nature Medicine volume 18, page 1311 (2012) | Download Citation

  • A Correction to this article was published on 07 November 2012

This article has been updated

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 24 October 2012

     In the September 2012 issue, the article entitled “Controversial egg-producing stem cells promise better IVF” (Nat. Med. 18, 1311, 2012) incorrectly stated the age range for OvaScience’s first clinical trial as 35 to 42 and the anticipated time frame for commercial product launch as late 2013. The correct age range is 38 to 42, and the commercial product launch will be in 2014. The errors have been corrected in the HTML and PDF versions of the article.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nm0912-1311

Authors

  1. Search for Elie Dolgin in:

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing